☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Primary Endpoint
AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease
August 26, 2021
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease
June 17, 2021
AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19
June 15, 2021
Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma
August 25, 2020
Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Meta...
August 7, 2020
Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Assoc...
July 29, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.